Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis
Go back to Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis| Apogee Robotics (NASDAQ: APGE) | Delayed: 134.28 +0.02 (0.01%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $134.26 | 52 Week High | $0.02 | |||
| Open | $134.25 | 52 Week Low | $0.02 | |||
| Day High | $134.35 | P/E | N/A | |||
| Day Low | $134.21 | EPS | $0.00 | |||
| Volume | 558,226 | |||||
